|Zuzanna Kłos, Magdalena Kujawiak, Maciej Chałubiński i wsp.|
Introduction. Granzyme B (GzmB) is well known serine protease mainly synthesized by cytotoxic T cells (CTL) and Natural Killer cells (NK) and mast cells.
Aim of the study. The aim of our study was to investigate granzyme B release from peripheral blood leukocytes, from patients with Hymenoptera venom allergy before and after ultra- rush immunotherapy.
Materials and methods. Nine patients allergic to wasp venom and qualified for ultra-rush specific immunotherapy with wasp venom allergen were recruited to the study. Leukocytes were isolated from blood and stimulated with wasp venom allergen (0.01µg/ml; 0.1µg/m and 1µg/ml) or honey bee venom allergen (1µg/ml).
Results. One hour after the highest dose of venom allergen injected during rush immunotherapy, more that 50% decrease in GzmB release was observed (non-singinficant). In vitro stimulation with specilif allergen (wasp venom) did not change mean GzmB concentration, however in some patients enhancement of GzmB release was noticed. Honey bee venom stimulation (non-specific allergen) increased mean GzmB concentration in both before and after immunotherapy.
Conclusion. GzmB is released from leukocytes of patients with wasp venom hypersensitivity and is decreased during specific treatment. Wasp venom and bee venom allergens may stimulate GzmB released in non-specific way.
keywords: cytotoksyczność, inhibitor PI-9, proteazy serynowe, zapalenie alergiczne, nadwrażliwość na jad owadów, cytotoxicity, PI-9 inhibitor, serine proteases, allergic inflammation, Hymenoptera venom hypersensitivity
pages: from 55 to 65
|estimated time of download (528 kB)|